User login
Key clinical point: Ever-smokers treated with the first-line pembrolizumab for advanced nonsmall cell lung cancer (NSCLC) have a significantly longer overall survival (OS) compared with never-smokers.
Major finding: Ever-smokers vs. never-smokers treated with the first-line pembrolizumab for advanced NSCLC had a 31% longer median OS (12.8 vs. 6.5 months; hazard ratio 0.69; 95% CI 0.50-0.95) after adjusting for covariates.
Study details: The data come from a real-world retrospective cohort study of 1166 patients with advanced NSCLC (91 never-smokers and 1075 current or former smokers [ever-smokers]) treated with the first-line pembrolizumab in the U.S.
Disclosures: No funding source was identified. The authors reported ties with one or more pharmaceutical companies or research organizations.
Source: Popat S et al. Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non–small cell lung cancer. JAMA Netw Open. 2022;5(5):e2214046 (May 25). Doi: 10.1001/jamanetworkopen.2022.14046
Key clinical point: Ever-smokers treated with the first-line pembrolizumab for advanced nonsmall cell lung cancer (NSCLC) have a significantly longer overall survival (OS) compared with never-smokers.
Major finding: Ever-smokers vs. never-smokers treated with the first-line pembrolizumab for advanced NSCLC had a 31% longer median OS (12.8 vs. 6.5 months; hazard ratio 0.69; 95% CI 0.50-0.95) after adjusting for covariates.
Study details: The data come from a real-world retrospective cohort study of 1166 patients with advanced NSCLC (91 never-smokers and 1075 current or former smokers [ever-smokers]) treated with the first-line pembrolizumab in the U.S.
Disclosures: No funding source was identified. The authors reported ties with one or more pharmaceutical companies or research organizations.
Source: Popat S et al. Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non–small cell lung cancer. JAMA Netw Open. 2022;5(5):e2214046 (May 25). Doi: 10.1001/jamanetworkopen.2022.14046
Key clinical point: Ever-smokers treated with the first-line pembrolizumab for advanced nonsmall cell lung cancer (NSCLC) have a significantly longer overall survival (OS) compared with never-smokers.
Major finding: Ever-smokers vs. never-smokers treated with the first-line pembrolizumab for advanced NSCLC had a 31% longer median OS (12.8 vs. 6.5 months; hazard ratio 0.69; 95% CI 0.50-0.95) after adjusting for covariates.
Study details: The data come from a real-world retrospective cohort study of 1166 patients with advanced NSCLC (91 never-smokers and 1075 current or former smokers [ever-smokers]) treated with the first-line pembrolizumab in the U.S.
Disclosures: No funding source was identified. The authors reported ties with one or more pharmaceutical companies or research organizations.
Source: Popat S et al. Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non–small cell lung cancer. JAMA Netw Open. 2022;5(5):e2214046 (May 25). Doi: 10.1001/jamanetworkopen.2022.14046